Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anthrax MedKit Initiative Could Learn From OTC Studies – NDAC

This article was originally published in The Tan Sheet

Executive Summary

FDA’s Nonprescription Drugs Advisory Committee recommends the HHS sponsors of an antibiotic MedKit take lessons from OTC drug development. But many advisory panel members at an April 2 meeting did not see clear benefits of allowing home stockpiling of doxycycline to treat anthrax.

You may also be interested in...



Merck, NDAC Chair Neill Cross Paths Again For Oxytrol Switch Meeting

Nonprescription Drugs Advisory Committee member Richard Neill in 2007 praised Merck’s Rx-to-OTC application for Mevacor while voting against the statin switch. On Nov. 9, Merck will try to convince now-chairman Neill and the rest of NDAC that overactive bladder drug Oxytrol can safely be sold OTC.

Merck, NDAC Chair Neill Cross Paths Again For Oxytrol Switch Meeting

Nonprescription Drugs Advisory Committee member Richard Neill in 2007 praised Merck’s Rx-to-OTC application for Mevacor while voting against the statin switch. On Nov. 9, Merck will try to convince now-chairman Neill and the rest of NDAC that overactive bladder drug Oxytrol can safely be sold OTC.

Merck Seeks Oxytrol Switch For Women As First Overactive Bladder OTC

Merck will present to FDA’s Nonprescription Drugs Advisory Committee Nov. 9 in support of switching Watson’s Oxytrol as a female-specific OTC.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS105674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel